汉商集团股份有限公司 二〇二四年度独立董事述职报告 ——独立董事 胡迎法 1、出席会议情况 2024 年，公司共召开了 7 次董事会会议，包括 2 次现场会议和 5 次通讯 会议，本人均亲自出席；本人会议出席率和参与决议事项表决率均为 100%。本 人认真审议提交董事会的议案，以谨慎的态度行使表决权，认为公司在 2024 年 度召开的董事会符合法定程序，重大经营决策事项和其它重大事项均履行了相 关程序，会议程序及所作决议合法有效，本人对年度内审议的董事会议案均投 了赞成票。 作为汉商集团股份有限公司（"汉商集团"或"公司"）的独立董事，本 人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上 市规则》（"《上交所上市规则》"）、《上市公司独立董事管理办法》等法 律法规和规范性文件的规定，以及汉商集团《公司章程》《独立董事工作制 度》等规定，切实履行独立董事忠实勤勉义务，积极为公司经营发展建言献 策，努力维护公司利益及全体股东特别是中小股东的合法权益。现将本人 2024 年度履行职责的具体情况报告如下： 一、独立董事基本情况 ...

汉商集团股份有限公司 二〇二四年度独立董事述职报告 ——独立董事 古继洪 作为汉商集团股份有限公司（"汉商集团"或"公司"）的独立董事，本 人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上 市规则》（"《上交所上市规则》"）、《上市公司独立董事管理办法》等法 律法规和规范性文件的规定，以及汉商集团《公司章程》《独立董事工作制 度》等规定，切实履行独立董事忠实勤勉义务，积极为公司经营发展建言献 策，努力维护公司利益及全体股东特别是中小股东的合法权益。现将本人 2024 年度履行职责的具体情况报告如下： 一、独立董事基本情况 本人履职后公司董事会审计委员会举行了 1 次会议，本人作为审计委员会 主任委员亲自出席。本人认真履行审计委员会的工作职责，参与和跟进了公司 定期报告的编制工作，审议通过了公司按照会计准则编制的财务报告等议案。 1、工作履历、专业背景及兼职情况 古继洪，男，1963 年 12 月出生，中共党员，博士研究生，正高级会计 师。1983 年 8 月至 2001 年 5 月，在铁道部大桥工程局四处工作，历任会计 ...

汉商集团股份有限公司 二〇二四年度独立董事述职报告 ——独立董事 胡浩 作为汉商集团股份有限公司（"汉商集团"或"公司"）的独立董事，本 人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上 市规则》（"《上交所上市规则》"）、《上市公司独立董事管理办法》等法 律法规和规范性文件的规定，以及汉商集团《公司章程》《独立董事工作制 度》等规定，切实履行独立董事忠实勤勉义务，积极为公司经营发展建言献 策，努力维护公司利益及全体股东特别是中小股东的合法权益。现将本人 2024 年度履行职责的具体情况报告如下： 一、独立董事基本情况 1、工作履历、专业背景及兼职情况 胡浩，男，1981 年 9 月出生，中共党员，研究生学历，硕士学位。2004 年-2008 年任滁州职业技术学院财务管理系讲师，2008 年至今历任宇业集团有 限公司董事长秘书，项目公司总经理。现任宇业集团有限公司常务副总裁，江 苏光宇兆能新能源科技有限公司董事长。 2、独立性情况自查说明 本人作为公司独立董事，未在公司兼任除董事会专门委员会主任委员或委 员外的其他职务， ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,175,401,780.87, a decrease of 15.41% compared to CNY 1,389,601,286.62 in 2023[22] - The net profit attributable to shareholders of the listed company was CNY -14,587,166.58, compared to CNY 61,206,384.07 in the previous year, indicating a significant decline[22] - The net profit after deducting non-recurring gains and losses was CNY -38,089,846.38, down from CNY 37,693,074.00 in 2023[22] - The cash flow from operating activities was CNY 192,778,247.22, a decrease of 22.01% from CNY 247,182,519.46 in the previous year[22] - The total assets at the end of 2024 were CNY 3,524,394,269.57, down 4.61% from CNY 3,694,821,482.47 in 2023[22] - The net assets attributable to shareholders of the listed company decreased by 0.87% to CNY 1,660,506,874.47 from CNY 1,675,094,041.05 in 2023[22] - The basic earnings per share for 2024 was CNY -0.0494, compared to CNY 0.2075 in 2023, indicating a shift to negative earnings[23] - The weighted average return on net assets was -0.87% for 2024, down from 3.67% in the previous year[23] Revenue Breakdown - Pharmaceutical business revenue was ¥790,630,187.56, down 20.54% year-on-year, while medical device revenue increased by 14.57% to ¥82,574,608.46[61] - The commercial operations segment generated revenue of ¥188,341,918.76, a decline of 12.94% year-on-year[61] - The exhibition business reported revenue of ¥70,245,750.09, reflecting a growth of 3.81% year-on-year[61] - Revenue from the digestive system segment was CNY 123.51 million, down 57.55% year-over-year, with a gross margin of 81.89%[104] - Revenue from the respiratory segment was CNY 227.76 million, down 3.12% year-over-year, with a gross margin of 61.90%[104] - Revenue from the anti-infection segment was CNY 183.31 million, down 16.53% year-over-year, with a gross margin of 14.42%[104] Market Trends and Strategy - The medical device market in China is projected to grow from 630 billion RMB in 2015 to 1.88 trillion RMB by 2025, with an annual compound growth rate of 11.5%[36] - The domestic market share of domestic brands in high-value consumables, such as artificial joints, increased by 19 percentage points from the first procurement to the 2024 renewal[36] - The company is advancing its "big health + big business" dual business strategy, emphasizing cost control and efficiency improvement[30] - The company is focusing on innovation and market expansion in response to the structural changes in the pharmaceutical industry, particularly in the demand for innovative drugs[130] Research and Development - The company has published 5 papers and presented 36 academic conference papers during the reporting period, indicating a commitment to research and development[31] - The company has a comprehensive R&D platform, with ongoing clinical trials for its innovative drugs expected to yield results by 2025[58] - The company is conducting Phase II clinical trials for the innovative drug DDCI-01, targeting pulmonary arterial hypertension and benign prostatic hyperplasia[105] - Total R&D investment for the year was CNY 45.09 million, with an expense ratio of 3.84% of revenue[112][115] Operational Developments - The company completed the resumption of production for 19 varieties across 9 production lines, resulting in 13 products being launched and sold during the reporting period[30] - The company is actively promoting the construction of new hospital facilities to enhance patient care environments[31] - The company has opened 3 shopping centers and 1 specialty store in Wuhan, with a total area of 35.37 thousand square meters[84] Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring equal rights for all shareholders, particularly minority shareholders[147] - The board of directors consists of 9 members, including 3 independent directors, and has established four specialized committees to enhance governance and oversight[148] - The company has implemented measures to avoid potential competition with its controlling shareholder by entering into a management contract for the operation of exhibition venue assets[149] - The company has a total of 44,256,815 shares under the employee stock ownership plan, indicating a commitment to employee engagement and retention[155] Environmental Responsibility - The company has established a mechanism for environmental protection and is classified as a key pollutant discharge unit[189] - The wastewater treatment process includes "high-concentration water regulation, mixed air flotation, hydrolysis acidification, secondary contact oxidation, activated sludge, contact oxidation, flocculation sedimentation, and artificial wetland," ensuring compliance with relevant environmental standards[192] - The company has improved its environmental management system, integrating environmental protection into daily operations and enhancing overall awareness among employees[197] Challenges and Risks - The company acknowledges high risks in R&D innovation, including high costs, long cycles, and low success rates, and plans to enhance risk management strategies to improve success rates in new drug and medical device development[144] - The company is closely monitoring industry policy changes to mitigate operational risks associated with drug production costs and profitability due to reforms in the pharmaceutical and medical device sectors[142]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 257,418,265.66, a decrease of 23.51% compared to CNY 336,558,236.01 in the same period last year[5] - Net profit attributable to shareholders was CNY 2,761,438.28, down 78.21% from CNY 12,671,739.22 year-on-year[5] - Basic earnings per share decreased by 78.14% to CNY 0.0094 from CNY 0.0430 in the same period last year[5] - Total operating revenue for Q1 2025 was ¥257.42 million, a decrease of 23.4% compared to ¥336.56 million in Q1 2024[26] - Net profit for Q1 2025 was ¥1.23 million, a decline of 87.3% from ¥9.62 million in Q1 2024[27] - The total comprehensive income for Q1 2025 was ¥1.23 million, a significant drop from ¥9.63 million in Q1 2024[27] Cash Flow - The net cash flow from operating activities was negative CNY 4,350,064.43, a decline of 107.95% compared to CNY 54,745,928.03 in the previous year[5] - Operating cash flow for Q1 2025 was negative at -¥4.35 million, compared to positive cash flow of ¥54.75 million in Q1 2024[30] - Cash inflow from operating activities totaled 194,882,122.09, compared to 263,062,501.37 in the same period last year, indicating a decrease of about 26%[40] - Cash outflow from operating activities was 178,895,582.44, down from 224,010,554.00, reflecting a reduction of approximately 20%[40] - The cash flow from financing activities for Q1 2025 was CNY 61,692,723.15, a significant improvement from a net cash outflow of CNY 51,657,920.84 in Q1 2024[31] - The net cash flow from financing activities was 42,356,460.48, a significant improvement compared to -49,062,450.57 in the previous year[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,606,523,833.04, an increase of 2.33% from CNY 3,524,394,269.57 at the end of the previous year[6] - The company's total liabilities increased to ¥1.80 billion in 2025 from ¥1.72 billion in 2024, reflecting a growth of 4.5%[23] - The company's total current liabilities reached CNY 1,498,629,755.67, up from CNY 1,428,511,817.17, which is an increase of approximately 4.9%[22] - The company's total assets as of March 31, 2025, amounted to CNY 2,785,516,683.11, up from CNY 2,756,353,497.56 at the end of 2024[34] - The company's total liabilities increased to CNY 1,094,933,122.23 as of March 31, 2025, compared to CNY 1,067,369,267.77 at the end of 2024[34] Investments and Expenses - Research and development expenses for Q1 2025 were ¥9.33 million, an increase of 29.9% compared to ¥7.18 million in Q1 2024[26] - The company reported a decrease in sales expenses to ¥32.31 million in Q1 2025 from ¥81.07 million in Q1 2024, a reduction of 60.1%[26] - The company reported a decrease in operating costs to CNY 7,915,401.95 in Q1 2025 from CNY 8,838,734.50 in Q1 2024, reflecting a cost reduction strategy[37] - The company’s cash outflow from investment activities totaled CNY 24,556,560.71 in Q1 2025, compared to CNY 62,612,081.33 in Q1 2024, indicating a reduction in investment spending[31] Shareholder Information - The company had a total of 16,547 common shareholders at the end of the reporting period[10] - Total equity attributable to shareholders rose slightly to ¥1.66 billion in 2025 from ¥1.66 billion in 2024, indicating a marginal increase of 0.05%[23] Legal and Compliance - The company has several accounts frozen due to legal issues, with a total balance of CNY 379,986.58 in one account as of March 31, 2025, which may impact liquidity[17] - The company has not adopted new accounting standards or interpretations starting from 2025[41]

众环专字(2025) 0101041 号 关于汉商集团股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 目 录 起始页码 l 专项审核报告 汇总表 上市公司 2024 年度非经营性资金占用及其他关联资 金往来情况汇总表 1 关于汉商集团股份有限公司 管性资金占用及其他关联资金往来情况汇总表 的专项审核报告 众环专字(2025)0101041 号 汉商集团股份有限公司全体股东: 我们接受委托,在审计了汉商集团股份有限公司(以下简称"汉商集团")2024年12月 31 日合并及公司的资产负债表,2024年度合并及公司的利润表、合并及公司的现金流量表 和合并及公司的股东权益变动表以及财务报表附注的基础上,对后附的《上市公司 2024年 度非经营性资金占用及其他关联资金往来的情况汇总表》(以下简称"汇总表")进行了专项 审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8号 -- 上市公司资金往 来、对外担保的监管要求》的规定,编制和披露汇总表、提供真实、合法、完整的审核证据 是汉商集团管理层的责任,我们的责任是在执行审核工作的基础上对汇总表发表专项审核意 见。 我们按照中国注册会 ...

拟续聘的会计师事务所名称：中审众环会计师事务所（特殊普通合伙） （以下简称"中审众环"） 一、拟聘任会计师事务所的基本情况 证券代码：600774 股票简称：汉商集团 编号：2025-021 汉商集团股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）机构信息 1、基本信息 （1）机构名称：中审众环会计师事务所（特殊普通合伙） （2）成立日期：中审众环始创于 1987 年，是全国首批取得国家批准具有从 事证券、期货相关业务资格及金融业务审计资格的大型会计师事务所之一。根据 财政部、证监会发布的从事证券服务业务会计师事务所备案名单，本所具备股份 有限公司发行股份、债券审计机构的资格。2013 年 11 月，按照国家财政部等有 关要求转制为特殊普通合伙制。 （3）组织形式：特殊普通合伙企业 （4）注册地址：湖北省武汉市武昌区水果湖街道中北路 166 号长江产业大 厦 17-18 楼 （5）首席合伙人：石文先 （6）2024 年末合伙人数量 216 人、注册会计师数量 1,304 人、签署 ...

投资者可于 2025 年 4 月 30 日（星期三）至 5 月 9 日（星期五）16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hshsd@126.com 进行提问。公司 将在说明会上对投资者普遍关注的问题进行回答。 证券代码：600774 股票简称：汉商集团 编号：2024-026 汉商集团股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 三、参加人员 公司出席本次说明会的人员有：副董事长杜书伟先生、独立董事古继洪先生、 副总经理兼董事会秘书、总会计师张镇涛先生及其他相关人员（参与人员可能会 根据情况调整）。 四、投资者参加方式 （一）投资者可在 2025 年 5 月 12 日下午 15:00-16:00，通过互联网登录上 证路演中心（http://roadshow.sseinfo.com/），在线参与本次业绩说明会，公 司将及时回答投资者的提问。 汉商集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 2 ...

证券代码：600774 股票简称：汉商集团 编号：2025-023 汉商集团股份有限公司 关于续展及新增担保额度的公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实、准确和完整承担法律责任。 重要内容提示： 1、担保范围：汉商集团股份有限公司（以下简称"公司"）与控股子公司或控股子公 司之间相互提供担保，包括：成都迪康药业股份有限公司、武汉国际会展中心股份有限公司、 重庆迪康中药制药有限公司、重庆迪康中科生物材料有限公司、重庆迪康长江制药有限公司、 成都芝草堂中药材有限公司、拉萨迪康医药科技有限公司、拉萨迪康生物材料有限公司、成 都迪康中科生物医学材料有限公司、汉商康养（湖北）有限公司、湖北黄龙湖分散式禅意酒 店管理有限公司、武汉华科生殖妇产医院有限责任公司、汉商粮油科技（湖北）有限公司 2、担保金额：自2024年年度股东大会审议通过之日起至2025年年度股东大会召开之 日 止，公司与控股子公司或控股子公司之间相互提供担保不超过 80,000万元，其中为资产负 债率低于70%（不含本数）的被担保方所提供担保的额度合计不超过60,000万元；为资产负 债率70%以 ...

汉商集团股份有限公司董事会 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，汉商集团 股份有限公司（以下简称"公司"）董事会，就公司报告期内独立董事胡迎法、 古继洪、胡浩的独立性情况进行评估并出具如下专项意见： 经核查报告期内独立董事胡迎法、古继洪、胡浩的任职经历以及签署的相 关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司 主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他 可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司独 立董事管理办法》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 中对独立董事独立性的相关要求。 汉商集团股份有限公司董事会 2025 年 4 月 29 日 ...